# US 2025/0154597 A1 · Transcriptional reprogramming differentiates active from inactive esr1 fusions in endocrine therapy-refractory metastatic breast cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154597 A1
- Document ID: US20250154597A1
- Status: Published application
- Kind: A1
- Application number: 18/700,510
- Filed: 2022-10-11
- Published: 2025-05-15
- Earliest claimed: 2021-10-12
- Assignees: Baylor College of Medicine
- Applicants: Baylor College of Medicine
- Inventors: Matthew J. Ellis; Xuxu Gou; Meenakshi Anurag; Jonathan T. Lei; Charles E. Foulds
- Web page: https://patentgrep.com/patent/US20250154597A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treatment, methods of detection, and kits associated with ERα+ cancer, such as ERα+ breast cancer, are disclosed herein. The methods and kits disclosed herein can assist physicians in relieving patient suffering by identifying cancer estrogen receptor status, and identifying appropriate therapeutic regimens in an individualized manner.

## Claims

### Claim at position 1

1-58. (canceled)

### Claim 59

A method of treating metastatic breast cancer comprising,
administering an effective amount of a non-ET resistant therapeutic regimen to a patient determined to have a biological sample with increased tumor cell expression of at least six genes selected from: ACOX2, ADCY1, ADRA2A, AFF3, AMZ1, BFSP2, BMPR1B, C14orf182, CALCR, CCDC88A, CD109, CD34, CHST8, COL3A1, CT62, CXCL12, DOK7, DSCAML1, ELOVL2, FLT4, FMN1, GATA4, GFRA1, GJA1, GREB1, GREM2, HEY2, IFITM10, IGF2, KCNH1, KRT13, MAPT, MDGA1, MPPED2, MYB, NKAIN1, NPY1R, NXPH3, OLFM1, PDZK1, PGLYRP2, PGR, PPP2R2C, PRSS56, RASGRP1, RBM24, RIMS4, ROBO3, SEMA3A, SERPINA6, SGK1, SLC47A1, SOX5, SPINK13, SPINK4, SPINK5, STC1, STC2, SUSD3, SYTL5, TFF1, TGM2, UGT3A2, VCAN, WT1, and ZNF385B.

### Claim at position 3

60-63. (canceled)

### Claim 64 (depends on 59)

The method of claim 59, wherein the patient is determined to have a biological sample with increased tumor cell expression of genes: ADCY1, GREB1, MYB, NPY1R, PGR, and TFF1.

### Claim 65

(canceled)

### Claim 66 (depends on 59)

The method of claim 59, wherein the method further comprises measuring expression levels of one or more internal controls, wherein the one or more internal controls comprise B2M, GAPDH, PSMC4, and/or PUM1.

### Claim 67

(canceled)

### Claim 68 (depends on 59)

The method of claim 59, wherein the level of gene activity is increased relative to a control and is identified using a nucleotide quantification assay.

### Claim 69

(canceled)

### Claim 70 (depends on 68)

The method of claim 68, wherein the nucleotide quantification assay comprises a labeled probe-based hybridization analysis assay or RNA sequencing.

### Claim 71 (depends on 70)

The method of claim 70, wherein the assay comprises one or more targeting probe/primers which comprises, or comprises a sequence complementary to, any one of SEQ ID NO: 1 to SEQ ID NO: 28.

### Claim 72 (depends on 70)

The method of claim 70, wherein the labeled probe-based hybridization analysis assay comprises a NanoString assay.

### Claim 73 (depends on 59)

The method of claim 59, wherein the cancer is ERα+ metastatic breast cancer (MBC).

### Claim 74 (depends on 59)

The method of claim 59, wherein the non-ET resistant therapeutic regimen comprises a CDK4/6 inhibitor.

### Claim 75 (depends on 74)

The method of claim 74, wherein the non-ET resistant therapeutic regimen further comprises one or more of a SERM, an aromatase inhibitor, and/or a SERD.

### Claim 76 (depends on 74)

The method of claim 74, wherein the CDK4/6 inhibitor is abemaciclib, palbociclib, or ribociclib.

### Claim 77

(canceled)

### Claim 78 (depends on 59)

The method of claim 59, wherein a reflexive diagnostic test is performed following tumor cell gene expression determination and prior to treatment regimen initiation.

### Claim 79 (depends on 78)

The method of claim 78, wherein the reflexive diagnostic test is selected from unbiased RNA-Seq, whole exome sequencing, ESR1-specific 3′ Rapid Amplification of cDNA ends (3′-RACE), and break-apart ESR1 fluorescence in situ hybridization (FISH).

### Claim at position 20

80-83. (canceled)

### Claim 84 (depends on 59)

The method of claim 59, wherein the administering of the non-ET resistant therapeutic regimen occurs within 1 month after tumor cell gene expression determination.

### Claim 85 (depends on 59)

The method of claim 59, wherein the biological sample is a primary tumor tissue sample or a metastatic tumor lesion sample.

### Claim at position 23

86-115. (canceled)

### Claim 116

A method for treating cancer in a patient, the method comprising administering a cancer therapy to the patient after determining whether the patient has a wild-type, mutant or translocated estrogen receptor alpha (ERα) protein by
measuring a biological sample from the patient for estrogen response gene expression and/or epithelial to mesenchymal transition (EMT) gene expression, wherein the cancer therapy comprises an effective amount of a CDK 4/6 inhibitor when the patient has a mutant or translocated estrogen receptor alpha ERα protein and wherein the cancer therapy comprises an effective amount of an Endocrine Therapy (ET) and a CDK 4/6 inhibitor when the patient has a wild-type ERα protein.

### Claim at position 25

117-120. (canceled)

### Claim 121 (depends on 116)

The method of claim 116, wherein determination of estrogen response gene expression comprises measuring expression levels of genes: ADCY1, GREB1, MYB, NPY1R, PGR, and TFF1.

### Claim at position 27

122-163. (canceled)

### Claim 164 (depends on 116)

The method of claim 116, wherein the CDK4/6 inhibitor is abemaciclib, palbociclib, or ribociclib and/or wherein the ET comprises one or more of a SERM, an aromatase inhibitor, and/or a SERD.

### Claim at position 29

165-186. (canceled)

### Claim 187

A kit comprising oligonucleotides capable of hybridizing to, and facilitating expression level determination of, at least six genes selected from: ACOX2, ADCY1, ADRA2A, AFF3, AMZ1, BFSP2, BMPR1B, C14orf182, CALCR, CCDC88A, CD109, CD34, CHST8, COL3A1, CT62, CXCL12, DOK7, DSCAML1, ELOVL2, FLT4, FMN1, GATA4, GFRA1, GJA1, GREB1, GREM2, HEY2, IFITM10, IGF2, KCNH1, KRT13, MAPT, MDGA1, MPPED2, MYB, NKAIN1, NPY1R, NXPH3, OLFM1, PDZK1, PGLYRP2, PGR, PPP2R2C, PRSS56, RASGRP1, RBM24, RIMS4, ROBO3, SEMA3A, SERPINA6, SGK1, SLC47A1, SOX5, SPINK13, SPINK4, SPINK5, STC1, STC2, SUSD3, SYTL5, TFF1, TGM2, UGT3A2, VCAN, WT1, and ZNF385B.

### Claim at position 31

188-191. (canceled)

### Claim 192 (depends on 187)

The kit of claim 187, comprising oligonucleotides capable of hybridizing to, and facilitating expression level determination of six genes: ADCY1, GREB1, MYB, NPY1R, PGR, and TFF1.

### Claim at position 33

193-246. (canceled)
